GH 35
Alternative Names: GH-35Latest Information Update: 17 Feb 2023
At a glance
- Originator Suzhou Genhouse Bio
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cancer
- Phase I Solid tumours
Most Recent Events
- 16 Feb 2023 Phase-II clinical trials in Cancer (PO) before February 2023 (Suzhou Genhouse Bio pipeline, February 2023)
- 24 Aug 2021 Pharmacodynamics data from preclinical trial in Solid tumours released by Suzhou Genhouse Bio (Suzhou Genhouse Bio's pipeline, August 2021)
- 18 Aug 2021 Preclinical trials in Solid tumours in China (PO) before August 2021